Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Devonian Health Group Inc DVHGF


Primary Symbol: V.GSD

Healthcare
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution... see more

Recent & Breaking News (TSXV:GSD)

Dr George G. Zhanel Joins Devonian's Cannabinoids Scientific Advisory Board.

Business Wire July 23, 2019

Devonian Announces the Filing of a New Patent Application Related to Use of Thylakoids as Delivery System for Cannabinoïds and Other Liposoluble Molecules

Business Wire June 5, 2019

Devonian Signs a Binding Letter of Intent with Histapharm Inc. to Extract and Manufacture Their Proprietary Botanical Pharmaceutical Product and to Enter into a Strategic Partnership for the Development of New Products

Business Wire June 3, 2019

Devonian Health Group Announces the Formation of a Scientific Advisory Board with Mandate to Assist in the Development of Cannabinoïds-Based Pharmaceutical Products.

Business Wire April 10, 2019

Groupe Santé Devonian annonce la création d'un conseil consultatif scientifique ayant pour mandat de contribuer au développement de produits pharmaceutiques à base de cannabinoïdes.

Business Wire April 10, 2019

Groupe Santé Devonian annonce la publication des résultats de l'évaluation in vitro des propriétés antioxydantes et de protection UV des extraits de thylakoïdes dans Journal of Cosmetic Dermatology.

Business Wire April 8, 2019

Devonian Health Group Announces the Publication of Results of in Vitro Assessment of the Antioxidant and UV Protection Properties of Thylakoid Extracts in Journal of Cosmetic Dermatology.

Business Wire April 8, 2019

Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019

Business Wire April 2, 2019

Groupe Santé Devonian rapporte ses Résultats Financiers clés pour le trimestre terminé le 31 janvier 2019.

Business Wire April 2, 2019

Groupe Santé Devonian émet des titres en règlement des intérêts dûs aux détenteurs de débentures et octroie des options

Business Wire April 1, 2019

Devonian Health Group Issues Securities in Interest Settlement Due to Debenture Holders and Grants Options

Business Wire March 29, 2019

Devonian Announces Voting Results of the Annual General and Special Meeting

Business Wire January 31, 2019

Groupe Santé Devonian annonce les résultats de l’Assemblée Générale Annuelle et Extraordinaire des Actionnaires

Business Wire January 31, 2019

Devonian Health Group Provides an Update on its Phase 2 Clinical Study in Atopic Dermatitis and Announces Plans for the First Photoprotection Product Issued From its Cosmeceutical R&D Program.

Business Wire January 29, 2019

Groupe Santé Devonian Fournit une Mise à Jour de son Étude Clinique de Phase 2 en Dermatite Atopique et Annonce son Programme pour le Premier Produit de Photoprotection issu de son programme de Recherche et Développement Cosméceutique.

Business Wire January 29, 2019

Groupe Santé Devonian annonce le refinancement du prêt pour ses installations pharmaceutiques

Business Wire January 23, 2019

Devonian Health Group Announces the Refinancing of the Loan on Its Pharmaceutical Facility

Business Wire January 23, 2019

Groupe Santé Devonian annonce la tenue de son Assemblée Générale Annuelle des Actionnaires pour 2018

Business Wire December 20, 2018

Devonian Health Group Announces 2018 Annual General Shareholder’s Meeting

Business Wire December 20, 2018

Groupe Santé Devonian annonce l’intronisation de Sybil Dahan, présidente d’Altius Healthcare, au Temple de la renommée canadien 2018 du marketing des soins de santé

Business Wire November 12, 2018